Monitor for future Form 4 filings by Robert Nelsen or ARCH Venture Fund XII, L.P. for any open-market purchases or sales, which would provide a clearer signal of insider conviction. The conversion of preferred shares upon an IPO is a key catalyst to watch.
Price Chart
Executive Summary
Robert Nelsen filed a Form 3 initial statement of beneficial ownership with City Therapeutics, Inc., disclosing indirect ownership of common stock and convertible preferred shares held through ARCH Venture Fund XII, L.P. This is a routine insider filing required upon becoming a beneficial owner and contains no material financial or operational information.
Key Facts
- Robert Nelsen filed a Form 3 initial statement of beneficial ownership with City Therapeutics, Inc. on October 15, 2026.
- Nelsen indirectly owns 2,718,292 shares of common stock, 3,294,900 shares of Series Seed convertible preferred stock, 5,482,309 shares of Series A convertible preferred stock, and 2,027,006 shares of Series B convertible preferred stock, all held through ARCH Venture Fund XII, L.P.
- Each share of preferred stock is convertible into common stock on a one-to-1.0983 basis, automatically upon the closing of the issuer's initial public offering.
- The filing includes a power of attorney authorizing Sebastian Trousil and Mary Beth DeLena to execute future Forms 3, 4, and 5 on Nelsen's behalf.
Financial Impact
No financial impact; the filing is a routine beneficial ownership disclosure with no transaction or material event.
Risk Factors
- No material risks identified from this routine filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-116351 |
| Document: 0001104659-26-116351-index-headers.html | 0001104659-26-116351 |
| Document: 0001104659-26-116351-index.html | 0001104659-26-116351 |
| Document: 0001104659-26-116351.txt | 0001104659-26-116351 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13D | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 26, 2026 1d ago | SC 13G | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 22, 2026 5d ago | SC 13G | $20.77 | awaiting T+5 | — | $20.86 (+0.43%) |
Oct 19, 2026 8d ago | Insider Cluster | $20.83 $20.86 | ▲ +0.14% | ▲ +0.06% | $20.86 (+0.14%) |
Oct 19, 2026 8d ago | Press Release | $20.83 $21.19 | ▲ +1.73% | ▲ +1.70% | $20.86 (+0.14%) |
Oct 16, 2026 11d ago | 424B4 | $21.46 $20.79 | ▼ −3.12% | ▼ −2.98% | $20.86 (−2.80%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers